Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 24590484)

1.

Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.

Di Maio VC, Cento V, Mirabelli C, Artese A, Costa G, Alcaro S, Perno CF, Ceccherini-Silberstein F.

Antimicrob Agents Chemother. 2014 May;58(5):2781-97. doi: 10.1128/AAC.02386-13. Epub 2014 Mar 3.

2.

HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors.

Cento V, Mirabelli C, Salpini R, Dimonte S, Artese A, Costa G, Mercurio F, Svicher V, Parrotta L, Bertoli A, Ciotti M, Di Paolo D, Sarrecchia C, Andreoni M, Alcaro S, Angelico M, Perno CF, Ceccherini-Silberstein F.

PLoS One. 2012;7(7):e39652. doi: 10.1371/journal.pone.0039652. Epub 2012 Jul 6.

3.

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.

Le Pogam S, Seshaadri A, Kosaka A, Chiu S, Kang H, Hu S, Rajyaguru S, Symons J, Cammack N, Nájera I.

J Antimicrob Chemother. 2008 Jun;61(6):1205-16. doi: 10.1093/jac/dkn085. Epub 2008 Mar 13.

4.

The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.

Alves R, Queiroz AT, Pessoa MG, da Silva EF, Mazo DF, Carrilho FJ, Carvalho-Filho RJ, de Carvalho IM.

J Viral Hepat. 2013 Jun;20(6):414-21. doi: 10.1111/jvh.12051. Epub 2013 Feb 6.

PMID:
23647958
5.

Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients.

Plaza Z, Soriano V, Gonzalez Mdel M, Di Lello FA, Macias J, Labarga P, Pineda JA, Poveda E.

J Antimicrob Chemother. 2011 Dec;66(12):2838-42. doi: 10.1093/jac/dkr385. Epub 2011 Sep 27.

6.

Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.

Aissa Larousse J, Trimoulet P, Recordon-Pinson P, Papuchon J, Azzouz MM, Ben Mami N, Cheikh I, Triki H, Fleury H.

J Med Virol. 2014 Aug;86(8):1350-9. doi: 10.1002/jmv.23958. Epub 2014 Apr 24.

PMID:
24760718
7.

Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.

Hang JQ, Yang Y, Harris SF, Leveque V, Whittington HJ, Rajyaguru S, Ao-Ieong G, McCown MF, Wong A, Giannetti AM, Le Pogam S, Talamás F, Cammack N, Nájera I, Klumpp K.

J Biol Chem. 2009 Jun 5;284(23):15517-29. doi: 10.1074/jbc.M808889200. Epub 2009 Feb 26.

8.

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.

Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK.

Hepatology. 2015 Jan;61(1):56-65. doi: 10.1002/hep.27375. Epub 2014 Nov 20.

PMID:
25123381
9.

Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women.

Dryer PD, Limketkai BN, Martin CM, Ma G, Sherman KE, Taylor LE, Mayer KH, Jamieson DJ, Blackard JT.

J Antimicrob Chemother. 2009 Nov;64(5):945-8. doi: 10.1093/jac/dkp328. Epub 2009 Sep 18.

10.

Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates.

Jaspe RC, Sulbarán YF, Sulbarán MZ, Loureiro CL, Rangel HR, Pujol FH.

Virol J. 2012 Sep 21;9:214. doi: 10.1186/1743-422X-9-214.

11.

Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.

López-Labrador FX, Moya A, Gonzàlez-Candelas F.

Antivir Ther. 2008;13(4):481-94.

PMID:
18672527
12.

Hepatitis C virus resistance to protease inhibitors.

Halfon P, Locarnini S.

J Hepatol. 2011 Jul;55(1):192-206. doi: 10.1016/j.jhep.2011.01.011. Epub 2011 Feb 1. Review.

13.

Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.

Howe AY, Cheng H, Johann S, Mullen S, Chunduru SK, Young DC, Bard J, Chopra R, Krishnamurthy G, Mansour T, O'Connell J.

Antimicrob Agents Chemother. 2008 Sep;52(9):3327-38. doi: 10.1128/AAC.00238-08. Epub 2008 Jun 16.

14.

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.

Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, Bruno R, Baldanti F.

Virol J. 2013 Dec 17;10:355. doi: 10.1186/1743-422X-10-355.

15.

Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1-5.

Legrand-Abravanel F, Henquell C, Le Guillou-Guillemette H, Balan V, Mirand A, Dubois M, Lunel-Fabiani F, Payan C, Izopet J.

Antivir Ther. 2009;14(5):723-30.

PMID:
19704176
16.

In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors.

Delang L, Vliegen I, Leyssen P, Neyts J.

J Hepatol. 2012 Jan;56(1):41-8. doi: 10.1016/j.jhep.2011.04.016. Epub 2011 May 20.

PMID:
21703175
17.

In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.

Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, Yan JM, So SS, Klumpp K, Nájera I.

J Infect Dis. 2014 Mar 1;209(5):668-75. doi: 10.1093/infdis/jit562. Epub 2013 Oct 23.

18.

An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors.

Caillet-Saguy C, Simister PC, Bressanelli S.

J Mol Biol. 2011 Dec 2;414(3):370-84. doi: 10.1016/j.jmb.2011.10.001. Epub 2011 Oct 8.

PMID:
22008450
19.

Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?

Halfon P, Sarrazin C.

Liver Int. 2012 Feb;32 Suppl 1:79-87. doi: 10.1111/j.1478-3231.2011.02716.x. Review.

PMID:
22212577
20.

Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study.

Jiao P, Xue W, Shen Y, Jin N, Liu H.

Mol Biosyst. 2014 Apr;10(4):767-77. doi: 10.1039/c3mb70498j. Epub 2014 Jan 23.

PMID:
24452008
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk